A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment With Individualized Dosimetry in Patients With 68Ga-DOTATATE Identified Somatostatin Receptor Positive Neuroendocrine Tumors
Not yet recruiting. Study Start Date: July 2016
Contact: Rebecca Wong, M.D. 416-946-2126
Juravinski Cancer Centre, Hamilton, Ontario, Canada
Contact: Rosalyn Juergens, M.D.
London Health Sciences Centre, London, Ontario, Canada
Contact: David Laidley, M.D.
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Contact: Rebecca Wong, M.D.
Sunnybrook Research Institute, Toronto, Ontario, Canada
Contact: Sten Myrehaug, M.D.
For more information on the trial: